Blood markers (sFlt-1/PlGF, sEng, OPG) for diagnosing and monitoring preeclampsia
Evaluation of sFlt-1/PlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
This study will test whether three blood markers—the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)—can help diagnose and track preeclampsia in pregnant women between 20 and 36 weeks of gestation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | University of Thi-Qar Academic / other |
| Locations | 1 site (Nasiriyah, Dhi Qar) |
| Trial ID | NCT07349277 on ClinicalTrials.gov |
What this trial studies
This observational cohort will enroll pregnant women at 20–36 weeks and collect blood samples to measure the sFlt-1/PlGF ratio, sEng, and OPG. Biomarker levels will be compared with clinical signs (blood pressure, proteinuria, and other maternal organ dysfunction) and timing of any preeclampsia diagnosis. Participants will be followed through delivery to record maternal and perinatal outcomes and treatments received. The aim is to see if these markers improve diagnostic accuracy or monitoring compared with standard clinical criteria.
Who should consider this trial
Good fit: Pregnant women aged 18–45 years between 20 and 36 weeks of gestation who attend the study antenatal clinic and do not have the listed exclusion conditions are ideal candidates.
Not a fit: People with chronic hypertension, renal disease, diabetes mellitus, multiple gestation, or autoimmune disorders were excluded and are unlikely to benefit from the findings of this protocol.
Why it matters
Potential benefit: If successful, these biomarkers could enable earlier and more accurate diagnosis and monitoring of preeclampsia, helping clinicians intervene sooner to reduce maternal and fetal complications.
How similar studies have performed: The sFlt-1/PlGF ratio has been validated in multicenter work (for example PROGNOSIS) as a strong predictor of preeclampsia, while evidence for sEng and OPG is promising but less conclusive.
Eligibility criteria
Show full inclusion / exclusion criteria
IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders
Where this trial is running
Nasiriyah, Dhi Qar
- Bint Al Huda Maternity Hospital — Nasiriyah, Dhi Qar, Iraq (Recruiting)
Study contacts
- Study coordinator: Ammar Jassim Abed, MSc
- Email: ammar.jassim11@gmail.com
- Phone: +9647809561105
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.